Phreesia vs Altria

Side-by-side comparison of AI visibility scores, market position, and capabilities

Altria leads in AI visibility (90 vs 36)

Phreesia

EmergingHealthcare

Patient Intake

NYSE-listed (PHR) patient intake platform digitizing check-in for 4,000+ practices at $383M revenue; pharma-funded activation programs competing with Epic and Clearwave for healthcare front-office engagement.

AI VisibilityBeta
Overall Score
D36
Category Rank
#1 of 1
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
45
Gemini
28

About

Phreesia is a Raleigh, North Carolina-based patient intake and engagement platform — listed on NYSE (NYSE: PHR) — providing healthcare practices, health systems, and pharmaceutical companies with digital tools for patient registration, insurance verification, payment collection, clinical pre-screening, and patient activation. Founded in 2005 by Chaim Indig and Evan Roberts and generating $383 million in revenue in fiscal year 2025 (ending January 2025), Phreesia serves 4,000+ healthcare practices and health systems with the patient-facing digital infrastructure that replaces paper clipboards and manual front-desk registration.

Full profile

Altria

LeaderConsumer Goods

Enterprise

Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#83 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
97
Gemini
99

About

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#1
Category Rank
#83
58
AI Consensus
58
stable
Trend
stable
39
ChatGPT
84
45
Perplexity
97
28
Gemini
99
37
Claude
86
30
Grok
87

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.